Dipartimento Di Scienze Mediche Traslazionali
- Address
- lock Available on a paid plan
Neurodevelopmental and Psychiatric Research
At the Dipartimento Di Scienze Mediche Traslazionali in Naples, clinical research is focused on nervous system diseases and mental disorders, with a strong emphasis on autism spectrum disorders. The studies are designed to better understand and improve core social and communication symptoms in children and adolescents, while also exploring how new approaches may support everyday functioning.
- Study of autism spectrum disorders in children and adolescents
- Assessment of social communication and interaction symptoms
- Evaluation of a potential new therapy for behavioral and developmental symptoms
This work reflects the site’s interest in combining psychiatry, psychology, and neurology to improve care for young people with neurodevelopmental conditions.
Rare Genetic and Pediatric Disease Studies
Another key area of research at this educational institution involves congenital, hereditary, and neonatal diseases, especially infantile-onset Pompe disease in pediatric patients. The trial work is centered on evaluating treatment safety and how well a new enzyme-based approach may help children with this rare inherited condition.
- Research in infantile-onset Pompe disease among children and adolescents
- Focus on treatment safety and tolerability
- Assessment of therapeutic effectiveness in rare pediatric disease
The research also supports broader efforts in pediatric medicine and rare disease therapy, with attention to improving outcomes for families affected by early-onset genetic disorders.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Amicus Therapeutics Inc.1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Dipartimento Di Scienze Mediche Traslazionali
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| An Open-label Study to Evaluate the Safety, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Cipaglucosidase Alfa/Miglustat in Both ERT-experienced and ERT-naïve Pediatric Subjects with Infantile-onset Pompe Disease Aged 0 to <18 Years | Amicus Therapeutics Inc. | Phase III | Recruiting | Nov 2024 | — |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cipaglucosidase Alfa | 1 | Unknown | 2024-11-04 | 2024-11-04 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.